Skip to main content
Premium Trial:

Request an Annual Quote

IP Holdings Founds New Company to Commercialize Applications for Human Gene

NEW YORK, April 5 (GenomeWeb News) - IP Holdings, a business incubator in Suffern, New York, has founded a company, Ryogen, that aims at commercializing applications for a recently patented human gene.

 

According to IP Holdings, the IP, which centers on the XPNPEP2 gene, "pertains to extensive segments of the human genome sequence and its applications to microarray manufacturing, gene testing and development of therapeutic agents."

The gene codes for the protein membrane-bound aminopeptidase P (AmP). The gene has received a US Patent, No. 6,399,349, entitled "Human Aminopeptidase P Gene."

 

IP Holdings claims the gene is a marker for hypertension, angioedema, rejection of kidney transplants, and certain tumors. The patent covers cDNA and gDNA sequences coding AmP; a method of producing AmP; the diagnostics for detecting AmP abnormalities; and prevention and treatment of medical conditions associated with the mutation of the AmP gene, IP Holdings said.

 

"We plan to pursue a comprehensive licensing program to ensure the broad proliferation of Ryogen's IP," said Alexander Poltorak, managing director of IP Holdings.

Ryogen is exploring a number of alternatives to license the AmP patent, including "ways to make this gene widely available for research so as to promote the development of genetic testing and treatment.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.